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Abstract
Background: Lassa hemorrhagic fever (LHF) is a neglected tropical disease with significant impact on the health
care system, society, and economy of Western and Central African nations where it is endemic. With a high rate of
infection that may lead to morbidity and mortality, understanding how the virus interacts with the host’s immune
system is of great importance for generating vaccines and therapeutics. Previous work by our group identified a
soluble isoform of the Lassa virus (LASV) GP1 (sGP1) in vitro resulting from the expression of the glycoprotein
complex (GPC) gene [1,2]. Though no work has directly been done to demonstrate the function of this soluble
isoform in arenaviral infections, evidence points to immunomodulatory effects against the host’s immune system
mediated by a secreted glycoprotein component in filoviruses, another class of hemorrhagic fever-causing viruses.
A significant fraction of shed glycoprotein isoforms during viral infection and biogenesis may attenuate the host’s
inflammatory response, thereby enhancing viral replication and tissue damage. Such shed glycoprotein mediated
effects were previously reported for Ebola virus (EBOV), a filovirus that also causes hemorrhagic fever with nearly
90% fatality rates [3-5]. The identification of an analogous phenomenon in vivo could establish a new correlate of
LHF infection leading to the development of sensitive diagnostics targeting the earliest molecular events of the
disease. Additionally, the reversal of potentially untoward immunomodulatory functions mediated by sGP1 could
potentiate the development of novel therapeutic intervention. To this end, we investigated the presence of sGP1
in the serum of suspected LASV patients admitted to the Kenema Government Hospital (KGH) Lassa Fever Ward
(LFW), in Kenema, Sierra Leone that tested positive for viral antigen or displayed classical signs of Lassa fever.
Results: It is reasonable to expect that a narrow window exists for detection of sGP1 as the sole protein shed during
early arenaviral biogenesis. This phenomenon was clearly distinguishable from virion-associated GP1 only prior to the
emergence of de novo viral particles. Despite this restricted time frame, in 2/46 suspected cases in two studies
performed in late 2009 and early 2010, soluble glycoprotein component shedding was identified. Differential detection
of viral antigens GP1, GP2, and NP by western blot yielded five different scenarios: whole LASV virions (GP1, GP2, NP; i.e.
active viremia), different combinations of these three proteins, sGP1 only, NP only, and absence of all three proteins.
Four additional samples showed inconclusive evidence for sGP1 shedding due to lack of detection of GP2 and NP by
western blot; however, a sensitive LASV NP antigen capture ELISA generated marginally positive signals
Conclusions: During a narrow window following active infection with LASV, soluble GP1 can be detected in
patient sera. This phenomenon parallels other VHF infection profiles, with the actual role of a soluble viral
glycoprotein component in vivo remaining largely speculative. The expenditure of energy and cellular resources
toward secretion of a critical protein during viral biogenesis without apparent specific function requires further
investigation. Future studies will be aimed at systematically identifying the role of LASV sGP1 in the infection
process and outcome in vitro and in vivo.
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Lassa virus, a member of the Arenaviridae family, is the
etiologic agent of Lassa fever, which is an acute and often
fatal illness endemic to West Africa. There are an esti-
mated 300,000 - 500,000 cases of Lassa fever each year,
with a mortality rate of 15% - 20% for hospitalized
patients and as high as 50% during epidemics [9,10]. Pre-
sently, there is no licensed vaccine or immunotherapy
available for preventing or treating this disease. Although
the antiviral drug ribavirin is somewhat beneficial, it
must be administered at an early stage of infection to
successfully alter disease outcome, thereby limiting its
utility [11]. Furthermore, there is no commercially avail-
able Lassa fever diagnostic assay, thereby inhibiting early
detection and rapid implementation of existing treatment
regimens (e.g. ribavirin administration). The lack of ade-
quate countermeasures and means of detection, coupled
with the severity of disease, contributed to the classifica-
tion of LASV as a National Institutes of Allergy and
Infectious Diseases (NIAID) Category A pathogen and
biosafety level-4 (BSL-4) agent. Presently, the Hemorrha-
gic Fever Virus Diagnostics Consortium is developing
and implementing highly sensitive and specific next gen-
eration recombinant diagnostic assays that will be easily
deployed and analyzed in remote locations of endemic
areas with few laboratory resources.
The LASV genome is comprised of two ambisense, sin-
gle-stranded RNA molecules designated small (S) and
large (L) [12]. Two genes on the S segment encode the
nucleoprotein (NP) and a precursor glycoprotein complex
(GPC). The L segment encodes the viral polymerase
(L protein) and RING finger Z matrix protein. The precur-
sor GPC forms the membrane-bound GP1 and GP2 subu-
nits via post-translational cleavage by the protease SKI-1/
S 1 P[ 1 3 ] .G P 1s e r v e sap u t a t i v er o l ei nr e c e p t o rb i n d i n g ,
while the structure of GP2 is consistent with viral trans-
membrane fusion proteins [14]. NP binds and protects the
viral RNA in the virion [15-17]. The Z matrix protein
associates with GP2 and NP during viral biogenesis, but
alone is sufficient to mediate formation and release of viral
particles from infected/transfected cells [18-21].
Results
Differential detection of LASV antigens in infected
human patient sera
A total of 19 and 27 patient sera were analyzed in the
first and second studies, respectively. A panel of serum
samples from approximately 100 volunteer blood donors
from the Northwestern district of Bombali, Sierra Leone,
designated BOM series, were analyzed for LASV-specific
antigen and IgG and IgM antibodies. These samples were
collected from individuals whose reported medical his-
tories did not contain indication of previous infection
with Lassa virus. A significant percentage of BOM sam-
ples tested positive for IgM and IgG antibodies against
LASV proteins in a recombinant ELISA, but all 100 were
negative for virus antigen in a capture assay using an NP-
specific detection platform (data not shown). Addition-
ally, a panel of archived and freshly collected human sera
from patients that had been admitted to the KGH from
January 2008 - April 2010 as suspected Lassa fever cases
were chosen for these studies. All archived samples con-
taining sufficient quantities of serum (~ 20 - 25 μL) with
a diagnosis of “antigen positive” (Ag+) determined by a
traditional Ag-capture assay (Trad Ag) developed by the
United States Army Medical Research Institute of Infec-
tious Diseases (USAMRIID), a recombinant Ag-capture
assay for LASV NP developed by the Hemorrhagic Fever
Virus Diagnostics Consortium, or from patients present-
ing with classical clinical symptoms of Lassa fever were
used in this study. In addition, a subpanel of samples that
were Ag-negative but IgM and/or IgG positive, either by
traditional LASV antibody platform (USAMRIID) [Trad
IgG, Trad IgM] or recombinant protein-based (Hemor-
rhagic Fever Virus Diagnostics Consortium) [r IgG,
r IgM] ELISA, were analyzed as controls. A profile of
LASV antigens detected in serum samples analyzed in
these studies is displayed in figure 1. All three antigens,
NP, GP1, and GP2, were detected at high levels in only
three patient sera (figure 1, G692-1, G762-1, G765-1).
The former two patients succumbed while the outcome
of G765-1 is unknown. In six independent patient sera,
GP1 antigen was the only antigen detected (figure 1,
G610-3, G676-A, G583-1, G755-1, G337-1, G079-3),
albeit at relatively low levels compared to the triple Ag-
positive samples. Samples G337-1 and G079-3 were not
analyzed for presence of the GP2 protein due to scarcity
of archived sera (figure 1). In two samples only, NP anti-
gen could be detected at low levels (figure 1, G787-1,
G090-3); however, GP2 analysis was not performed for
the latter. In 34 patient and control sera, none of the
t h r e eL A S Vp r o t e i n sw e r ed e t ected, as outlined in the
three examples in figure 1 (figure 1, G543-3, BOM011,
BOM019). Identification of LASV proteins NP, GP1, and
GP2 in patient sera was aided by comparing correspond-
ing bands on VLP (figure 1, LASV VLP). The 42 kDa
sGP1 component generated from expression of GPC in
HEK-293T/17 cells was precipitated from the superna-
tant with PEG and salt and readily detected (figure 1,
GPC 36 h). Viral proteins could not be detected in preci-
pitated supernatants from cells transfected with plasmid
vector (figure 1, pcDNA).
In figures 2 and 3 western blot results were compared
to available data generated with recombinant and tradi-
tional LASV antigen capture, IgM, and IgG assays.
Figure 2A displays western blot data for GP1, GP2, and
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Page 2 of 11NP, whereas figure 3A lacks GP2 analysis. Antigen cap-
ture data using the traditional assay platform are dis-
played in figures 2B and 3B, and contain averaged A450
absorbance values for test patient, positive, and negative
control sera. For each set of samples, the data were not
normalized due to the lack of internal assay calibrators
and analysis of patient sera on different dates concur-
rent with collection and analysis at the KGH. In these
studies, presence of sGP1 as the sole detectable arena-
viral antigen in serum samples was established only
when both GP2 and NP could not be equally detected.
Exclusionary parameters for sole detection of sGP1 were
positive results in a traditional capture assay employing
GP1, GP2, and NP-specific mAb cocktails, in a recombi-
nant NP antigen capture platform, and detection of
other viral components in western blots, as outlined in
methods. The only two samples that met these
criteria in the current studies were G610-3 and G755-1
(figure 1, 2A, 2B, 2C).
Discussion
In previous studies we described and characterized the
phenomenon of LASV GP1 ectodomain shedding
in vitro [1,2]. In order to investigate whether this phe-
nomenon was specific in vivo,w ea n a l y z e ds e r u ms a m -
ples from patients admitted to the KGH in Sierra Leone
from 2008 - 2010 for the differential detection of LASV
proteins. Our approach involved the detection of GP1,
GP2, and NP in the same sample, with sensitive mono-
clonal and polyclonal antibodies. The detection of NP
alone could be indicative of release of the protein from
virally infected dead cells, and could conceivably remain
in the bloodstream after viral clearance. This phenom-
enon has been observed in vitro [16,22]. Thus, acute vir-
emia was characterized as the concomitant detection of
all three viral proteins, GP1, GP2, and NP. The detec-
tion of GP2 implies its presence in the context of an
enveloped virion, due to its known membrane-spanning
properties via the transmembrane domain (amino acids
427 - 451 in LASV Josiah). Similarly, the presence of
GP1 in the same samples would imply viremia because
it associates with GP2 as a component of the non-cova-
lently linked tripartite GPC complex. The nucleoprotein
component of the virion should also be detected in all
samples containing GP1 and GP2, thus confirming the
presence of intact, enveloped, circulating Lassa virions.
The detection of only GP1 in any given sample was
interpreted as the absence of whole virions and the pre-
sence of the soluble form of the protein, as previously
observed in vitro. The date and time of collection of any
given blood sample represents a snapshot in the stage of
a potential LASV infection. Within the context of an
early acute viral infection, it is unlikely that a patient
would present with symptoms immediately following
exposure to the virus. Following viral infection of host
cells and early replication events, the detection of sGP1
without accompanying progeny virions might be possi-
ble. This event may represent a very narrow window in
the virus life cycle before the emergence of mature vir-
ions from infected cells in vivo.T h u s ,t h er a t i oo f
Figure 1 Western blot analysis of LASV antigen positive and negative patient sera and controls for GP1, GP2, and NP proteins. Twenty
μL of a 1:4 dilution of precipitated suspected LASV patient sera were resolved per lane of a reducing SDS-PAGE gel, blotted and probed with
a-GP1, a-GP2, or a-NP antibodies. In three samples NP, GP1, GP2 were detected, indicating presence of LASV virions (G692-1, G762-1, G765-1;
NP, GP1,2 (+)). In G610-3, G676-A, G583-1, and G755-1 only GP1 was detected (GP1 (+)). Only low levels of NP were detected in G787-1 (NP (+)).
Whereas in G337-1 and G079-3 only GP1 was detectable (GP1 (+)), GP2 levels were not determined (nd). Similarly, in G090-3 only low levels of
NP were detected, but GP2 levels were not determined (nd). A representative suspect LASV patient serum sample that did not reveal detectable
levels of all three viral antigens (G543-3) is shown alongside normal uninfected controls (BOM011, BOM019) (NP, GP1,2 (-)). In vitro controls
derived from transfection of HEK-293T/17 cells with pcDNA vector (pcDNA) or a LASV GPC construct harvested at 36 hours (GPC 36 h) are
shown. Soluble GP1 can be precipitated from the supernatants of cells expressing GPC (GPC 36 h). LASV VLP containing NP, GP1, and GP2 are
shown for protein size comparison (L VLP) (in vitro ctrls). Molecular weights for each LASV protein are shown to the left of blots, and identified
on the right.
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Page 3 of 11Figure 2 Antigen, IgG, IgM, and outcome profiles in suspected LASV patient sera from the first study (December 2009): G079-3
through G617-1. A. Trad Ag, IgG, IgM (USAMRIID), and r Ag, IgG, IgM (Hemorrhagic Fever Virus Diagnostics Consortium) were ELISA platforms,
whereas GP1, GP2, NP WB were western blots. The USAMRIID assays were performed before the recombinant counterparts, sometimes months
in advance. Western blot analyses were performed on samples shipped to the U.S. following irradiation. A very strong positive signal is indicated
by ++ and a positive by +. Marginal positive detection is indicated by +/- and negatives by -. Gray boxes indicate that relevant data was not
collected for the corresponding sample. Patient outcomes recorded in databases are: d, discharged; D, dead; na, not admitted; c, household
contact of patient G676; ?, patient samples from Liberia, with unknown outcome. Non applicable (N/a) outcome is indicated for in vitro controls.
B. Traditional antigen (Trad Ag) data showing the A450 O.D. for all samples (blue) alongside positive (dark red) and negative (green) controls.
Data are plotted as mean ± SD, n = 2. Each sample in this series was analyzed on different days, concurrent with testing of suspect patients
admitted to KGH. Collection dates for this series ranged from January 2008 to September 2009.
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Page 4 of 11Figure 3 Antigen, IgG, IgM, and outcome profiles in suspected LASV patient sera from the second study (March and April 2010):
G543-3 through G806-1. A. The legend and designations outlined in figure 2A above apply to figure 3. Sample G598-2 was duplicated in this
series to verify previous results. B. Traditional antigen (Trad Ag) data as outlined for figure 2B above. Data are plotted as mean ± SD, n = 2. Each
sample in this series was analyzed on different days, concurrent with testing of suspect patients admitted to KGH. Collection dates for this series
ranged from June 2009 to March 2010.
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Page 5 of 11samples where sGP1 alone was conclusively detected in
the context of these studies was small (2/46). Following
this very early step in viral biogenesis where host cells
are secreting only sGP1, progeny virions will emerge
from the surface of infected cells and will disseminate
throughout body tissues and fluids. At this stage, differ-
entiation of sGP1 from virion-associated GP1 is no
longer possible. In the cases where any viral antigens,
IgM and IgG were detected (G692-1, G762-1, G765-1),
the possibility exists that a re-infection with clinical
symptoms and development of febrile disease occurred.
Two out of these three patients succumbed to Lassa
fever; the outcome of patient G765-1 is not known.
Each sample analyzed in these studies for LASV anti-
gens was exhaustively subjected to western blot analysis
with different viral protein-specific antibody reagents, at
different serum dilutions, with extended exposures to
sensitive films, and using an extensive panel of positive
and negative controls to ensure that data were not the
result of artefacts or background effects. Therefore, each
sample was analyzed for presence of each antigen at
least three times, either in a primary detection or in
probing and reprobing formats. Although probing and
reprobing allowed for the detection of antigens using a
single blot, and thus preserving precious sample
volumes, the membrane stripping process removes pro-
tein from the matrix, thus reducing the sensitivity of
subsequent assays. The small volumes of available
serum for analysis made further characterization of each
sample unfeasible. Future studies will be aimed at char-
acterizing the nature of shed sGP1 in vivo, namely pro-
teolysis sensitivity and deglycosylation analyses, for
which relevant in vitro data is available.
In these studies three sets of relevant data were used
to interpret the antigenic status of the serum samples: 1.
Traditional antigen (Trad Ag) ELISA; 2. Recombinant
antigen capture, NP-specific; 3. Western blot analysis of
GP1, 2 and NP. Direct correlations cannot be made
between the three assay platforms based on several fac-
tors. The USAMRIID antigen capture assay employs
two GP1-, two GP2-, and one NP-specific mAbs [24].
Thus, individual identification of each antigen cannot be
established. Furthermore, this assay relies on a two-step
signal amplification and detection, each with polyclonal
antibody reagents, a rabbit secondary and a goat tertiary.
The sensitivity of this assay, therefore, may be superior
to the recombinant NP mAb-based antigen capture for-
mat, which employs a single detection step with a goat
polyclonal raised against recombinantly expressed NP
protein. Both antigen capture formats were performed
with 1:10 dilutions of serum in assay buffer, in a total of
100 μL. Then, western blots were performed with preci-
pitated protein from 5 μL of serum. Considering that
each analytical format detects antigens in different
conformations, direct data comparison is not feasible.
Despite specificity and sensitivity issues at play, in 21/30
samples for which data is available from all three assay
formats, the results from the Trad Ag and r Ag plat-
forms agreed. In six samples, the Trad Ag assay detected
LASV antigen and the r Ag platform did not. The
higher sensitivity of the former may be due to the com-
bination of 3 antigen-specific mAbs that detected LASV
glycoproteins in addition to NP in the Trad Ag assay.
Another possibility to consider is the quality of stored
samples in less than ideal conditions over extended peri-
o d so ft i m e .T h el a c ko fc o n t i n u o u se l e c t r i c a lp o w e ra t
the KGH over the years has resulted in temperature
fluctuations in refrigerators and freezers, which may
interfere with sample quality and stability of viral anti-
gens. The time that elapsed between collection and ana-
lysis of samples used in these studies varied between 3
months and 2 years. Despite these technical issues,
many samples that originally tested positive for antigen,
IgM, and IgG, retain the specific binding pattern irre-
spective of the time elapsed since collection. A complete
list of samples, dates of collection, antigen status, and
known storage temperature are shown in Table 1. The
two samples in which only sGP1 could be detected in
these studies (G610-3 and G755-1) were collected in
September 2009 and January 2010, and thus analyzed
within 3 months of collection, in December 2009 and
April 2010, respectively.
Nine samples tested positive for sGP1 by western blot
(G079-3, G337-1, G583-1, G610-3, G676-A, G692-1,
G755-1, G762-1, G765-1). In three additional samples,
the r Ag assay marginally detected NP in serum samples
(G652-3, G803-1, G803-2). However, these three sam-
ples did not test positive for sGP1 or NP by western
blot. Our data suggests that a NP-based Ag capture
a s s a yc u r r e n t l yi nu s eh a sas e n s i t i v i t yt h r e s h o l do f1 . 5
ng rNP/mL (unpublished data). Western blots have not
thus far successfully detected NP Ag in the low ng/mL
level. Three other samples tested positive in the Trad
Ag and r Ag ELISA assays, along with detection of sGP1
by western blot analysis, but did not test positive for NP
by western blot, and were, therefore, not considered
examples of glycoprotein shedding (G079-3, G337-1,
G583-1). In this group of samples only G583-1was ana-
lyzed for presence of GP1, GP2, and NP, whereas the
remaining two were not tested for GP2. Despite the
absence of GP2 by western blot, the presence of NP by
antigen capture ELISA and the fact that it was positive
by the traditional antigen capture ELISA made it impos-
sible to distinguish between the phenomenon of sGP1
shedding and the presence of GP1 in enveloped virion
format. Thus, we have considered samples G610-3 and
G775-1 as the only examples of clear LASV GP1 shed-
ding in these studies, though the phenomena of GP1
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Page 6 of 11Table 1 Collection and sample processing dates for G-series samples
Sample
ID
Date of
collection
Date
processed
Comments rAg status Sample storage temperature
G079-3 16-Jan-08 December
2009
Expired NP, GP1 +10°C to -5°C, fluctuating w/power availability at KGH LFL
G090-2 01-Feb-08 Discharged
G090-3 02-Feb-08 NP (WB)
G106-1 19-Feb-08 Discharged
G153-1 07-May-08 Expired
G165-1 15-May-08 Expired
G193-1 16-Jun-08 Expired NP (ELISA)
G327-2 17-Dec-08 Discharged NP (ELISA), GP1
G337-1 12-Jan-09 Not admitted
G408-2 12-Feb-09 Discharged
G418-11 22-Jul-09 Follow-up
G443-12 Apr-09 Follow-up
G540-4 May-09 Discharged
G543-3 24-Jun-09 Discharged
G548-1 21-Jun-09 Expired
G551-3 28-Jun-09 Discharged
G579-1 13-Jul-09 Expired
G583-1 16-Jul-09 Discharged NP (ELISA), GP1
G590-1 24-Jul-09 Expired
G598-2 19-Aug-09 Not admitted
G610-1 27-Aug-09 Discharged
G610-3* 03-Sep-09 GP1
G617-1 15-Sep-09 Discharged
G645-2 24-Oct-09 Discharged
G652-3 02-Nov-09 Discharged NP (ELISA, ±)
G676-A Dec-09 Contact of
G676
GP1
G692-1 31-Dec-09 April 2010 Expired NP (ELISA, WB), GP1,
GP2
-20°C, consistent temperature, power supplied by solar panel
array 24 hours/day
G693-1 31-Dec-09 Expired
G706-1 07-Jan-10 Discharged NP (ELISA)
G753-1 27-Jan-10 Discharged NP (ELISA)
G755-1* 27-Jan-10 Not admitted GP1
G756-1 27-Jan-10 Discharged NP (ELISA,±)
G762-1 29-Jan-10 Expired NP (ELISA, WB), GP1,
GP2
G765-1 06-Feb-10 Unknown
outcome
NP (ELISA, WB), GP1,
GP2
G771-1 08-Feb-10 Expired NP (ELISA)
G784-1 17-Feb-10 Expired NP (ELISA)
G787-1 18-Feb-10 Unknown
outcome
NP (WB, ±)
G793-1 24-Feb-10 Discharged
G795-1 25-Feb-10 Unknown
outcome
G802-1 25-Feb-10 Discharged
G803-1 25-Feb-10 Discharged NP (ELISA)
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Page 7 of 11shedding may occur throughout viremia. In both sam-
ples, LASV antigen was not detected by Trad Ag and r
Ag ELISA, and western blot did not reveal presence of
GP2 and NP. However, GP1 was clearly present (figure
1, G610-3, G755-1). For sample G676-A, collected from
a household contact of patient G676 who succumbed to
Lassa fever, Trad Ag and r Ag ELISA data were not
available; therefore, this sample was also not considered
a clear example of GP1 shedding.
Based on the proposed narrow window of sGP1 detec-
tion in vivo likely to occur in the first few days after pri-
mary infection with LASV, it is not surprising that only
2/46 samples analyzed in these studies would not show
any other viral proteins indicating an early LASV infec-
tion. The known incubation period for infection with
LASV is approximately 6 - 7 days [24,25]. However,
admission to local hospitals is usually delayed following
the onset of febrile disease compounding the low detec-
tion rate of shed GP1. Thus, in many cases, patients
admitted to the KGH present with acute viremia, or
undetectable antigen but rising IgM titers, indicative of
advanced LASV infection.
Strecker et al., 2003 [19] reported the stoichiometric
ratio of NP:GP1:GP2 in Lassa virions as 160:60:60. In
the context of a LASV virion, detection of one protein
should result in the detection of the other two. Thus,
detection of GP1 without concomitant detection of
either GP2 or NP can be interpreted as a secreted iso-
form of GP1 prior to but not necessarily limited to the
emergence of enveloped viral particles from infected
cells, that likely corresponds to the sGP1 component
identified in vitro (figure 1, GPC 36 h) [1,2]. Although
the possibility exists that sole detection of sGP1 in
serum samples is the result of degraded virions or viral
protein released from infected cells, recent studies with
LASV VLP suggest differently. The structure and func-
tion of arenaviral glycoproteins have resulted in signifi-
cant resistance to proteolytic digestion with highly
active proteases, namely trypsin and Proteinase K [26].
We and others have observed that glycosylated LASV
GP1 and GP2 are highly resistance to the effects of pro-
teolytic digestion, whereas NP and Z are not. Thus,
degraded virions that afford detection of GP1 should
also result in equivalent detection of GP2, despite the
loss of NP (and Z). Moreover, lysis of infected cells
in vivo would parallel the effects of in vitro LASV infec-
tion, but selective release of the GP1 protein is highly
unlikely. If GP1 generated during viral biogenesis is
released from lysed cells, concomitant detection of GP2
and NP should be observed. Generation of LASV VLP
in mammalian cells via transfection with GPC, NP, and
Z gene constructs resulted in pseudoparticles containing
all three proteins closely associated in enveloped struc-
tures. Additionally, sGP1 and a minor soluble NP frac-
tion, but not Z or GP2, could be detected in the least
dense sucrose fraction in gradient centrifugation assays,
indicating their lack of association with enveloped pseu-
doparticles [26]. Release of NP from dead cells was
observed in the studies by Branco et al. [26] and by and
others [22]. Conversely, soluble GP1, but not GP2,
could be readily detected in the supernatant as early as
12 hours after transfection with GPC constructs in vitro.
Release of NP from transfected cells was not observed
in the context of single gene transfections [26].
Together, these results strongly suggest that a soluble
GP1 component can be secreted from cells expressing
the LASV glycoprotein complex prior to release of
mature virions in vivo. A graphic model outlining a pro-
posed temporal progression of virus infectivity of per-
missive cells, glycoprotein display and sGP1 shedding,
relevant protein components in LASV virions, and
release of viral components from dead cells is shown in
figure 4.
Conclusions
Through this work, we have identified a soluble form of
L A S VG P 1i nt h es e r u mo fi n f e c t e dp a t i e n t s .A l t h o u g h
the exact stage of viral infection in all patients could not
be determined through these studies, the lack of detec-
tion of the virion associated NP and GP2 proteins, with
clear identification of GP1 in the serum of acutely
infected individuals, points to an early event in viral
replication when only sGP1 can be detected. Although a
role for sGP1 in arenaviral infections in vivo has not
Table 1 Collection and sample processing dates for G-series samples (Continued)
G803-2 27-Feb-10 Discharged NP (ELISA)
G804-1 26-Feb-10 Discharged
G806-1 25-Feb-10 Expired
G808-1 27-Feb-10 Discharged NP (ELISA)
BOM011 Apr-10 Healthy
volunteer
BOM019 Apr-10 Healthy
volunteer
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Page 8 of 11been established, future work will attempt to character-
ize functional roles for this protein. It is likely that
LASV sGP1 performs immunomodulatory and decoy
functions similar to those proposed for EBOV, a filo-
virus; respiratory syncytial virus (RSV), a paramyxovirus;
human immunodeficiency virus (HIV), a retrovirus; and
rabies virus (RABV), a rhabdovirus. In EBOV and RSV
infections it has been proposed that ectodomain shed-
ding of the viral envelope glycoprotein serves as an
immune decoy, with significant enhancement of patho-
genicity in vivo [3,27].
Definition of the role(s) of LASV sGP1 in vivo could
lead to new correlates of the disease, opportunities
toward development of diagnostics targeting early events
in acute infection and viral biogenesis, and the ability to
counter potential viral immunomodulatory pathways
that confer poor outcomes.
Methods
Human serum collection
Febrile patients suspected of having LF were admitted to
the LF Ward at the Kenema Government Hospital
(KGH) in Kenema, Sierra Leone. Informed consent was
obtained and each patient was assigned a unique identi-
fication number (G-XXXX). Approximately 5-10 ml of
blood was collected from each patient. Blood was
Figure 4 Graphic model of glycoprotein display and sGP1 shedding, relevant protein components in LASV virions, and release of viral
components from dead cells. (1) LASV glycoprotein mediates virion binding to alpha dystroglycan (aDG) on permissive cells (1a). Following
receptor binding the virion fuses with the host cell membrane, resulting in viral entry. Viral replication takes place in the cytoplasm of the
infected cell. (2) During replication and before mature virions are assembled GPC is proteolytically processed and a portion of the resulting GP1
is transported to the cell surface and shed as sGP1 (2a). Concurrently, GPC is expressed on the cell surface, mediated by GP2 anchoring in the
bilipid membrane, non-covalently associated GP1, and the hydrophobic signal peptide (2b). (3) Budding virions emerge from the cell surface
mediated by Z matrix protein as enveloped particles containing membrane lipid and proteins, viral GPC and nucleoprotein. (4) Virions are
released from infected cells containing nucleoprotein and associated viral RNA segments, along with non-displayed polymerase and cellular
ribosomes. Budded virions will enter the circulation and can be detected in whole antigen capture assays or by western blot identification of
individual proteins, as performed in these studies. Presence of intact virions should permit the identification of GP1, GP2, and nucleoprotein. (5)
Nucleoprotein and glycoproteins can shed from dead or dying cells, with compromised cell membrane integrity. This phenomenon is observed
in vitro, and may occur in vivo, hence the detection of only NP in some serum samples. A graphic representation of each relevant component in
the outlined pathway is shown in the legend box. EC: extracellular; IC: intracellular; CM: cell membrane.
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Page 9 of 11collected into 5 ml serum collection tubes using butter-
fly safety needles. The same procedures and assurances
were employed in the collection of blood from normal
human volunteers. Normal human sera used in these
studies were collected in the Bombali district of North-
ern Province, Sierra Leone, and designated BOM.
Precipitation of total protein from human serum samples
Serum samples collected from patients admitted to the
KGH Lassa fever ward (G-series), household contacts of
hospitalized subjects (G-series-A), and individuals not
known to have had Lassa fever (BOM) were aliquoted
and stored in cryovials at the KGH Lassa fever labora-
tory. Samples used in these studies were visually
inspected for presence of follicular precipitate, coagulate,
significant discoloration, contamination, and haemolysis.
Only clear serum samples were used. Twenty μL of each
serum sample were diluted 5-fold with sterile D-PBS,
pH 7.4 and combined with 20% polyethylene glycol-
6000 (PEG-6000) and 2 M NaCl stock solutions to final
concentrations of 5% and 0.2 M, respectively. Samples
were incubated at 4°C overnight, followed by centrifuga-
tion at 21,000 ×g,f o r7 5m i n u t e sa t4 ° C .S u p e r n a t a n t s
were carefully aspirated and discarded. Pellets were
resuspended in SDS-PAGE buffer with 50% glycerol,
heated without reducing agent, and stored frozen until
shipment. Samples were shipped to the U.S. in IATA-
approved containers and were irradiated with 2500
KRad upon arrival, using a Cs source. Recombinant
LASV VLP expressing Z+NP+GPC were used as con-
trols for identification of viral proteins in SDS-PAGE,
along with soluble GP1 (sGP1) from HEK-293T/17 cells
transfected with a wild type GPC gene. The generation
of LASV VLP and sGP1 have been described elsewhere
[1,2,26].
Western blot analysis
Four-fold dilutions of protein sample from a 20 μL
serum aliquot were prepared in SDS-PAGE sample buf-
fer, reduced with DTT, heated to 75°C for 10 minutes,
and resolved on 10% NuPAGE Novex Bis-Tris gels,
according to the manufacturer’s specifications (Novex,
San Diego, CA). Proteins were transferred to 0.45-μm
nitrocellulose membranes, blocked, and probed in 1X
PBS, pH 7.4, 5% non-fat dry milk, 1% heat inactivated
fetal bovine serum, 0.05% Tween-20, and 0.1% thymero-
sal. Detection of LASV GP1, GP2, and NP in precipi-
tated protein from human serum samples was
performed by Western blot analysis using anti-LASV
mAbs L52-74-7A (GP1), L52-216-7 and L52-272-7
(GP2), and goat PAb to E. coli generated nucleoprotein,
respectively. Secondary antibodies were horseradish per-
oxidase (HRP)-conjugated goat anti-mouse IgG (H+L)
or rabbit anti goat IgG (H+L). Membranes were then
incubated in LumiGlo chemiluminescent substrate
(KPL) and exposed to HyBlot CL Film (Denville Scienti-
fic, Inc). Blots used in reprobing experiments were
briefly rinsed in PBS-T (1X PBS, pH 7.4, 0.1% Tween
20) after exposure to x-ray film, followed by incubation
in stripping buffer (62.5 mM Tris, pH 6.8, 2% SDS, 100
mM b-ME) for one hour at 65°C. Blots were then
washed extensively in PBS-T, re-blocked, and reprobed
as outlined above. Blots were reprobed a maximum of
three times.
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